Ecopetrol SA vs Zimmer Biomet Holdings Inc — how do they compare? Ecopetrol SA trades at $17.01 (market cap $34.97B), while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.65B). The key difference: Ecopetrol SA is the larger of the two by market cap, and Ecopetrol SA pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| EC | ZBH | |
|---|---|---|
Market Cap | $34.97B | $18.65B |
Sector | Energy | Health |
52-Week High | $17.40 | $107.71 |
52-Week Low | $8.56 | $79.58 |
Enterprise Value | $65.28B | $25.72B |
Dividend Yield | 3.81% | 0.98% |
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.78, down 3.56% on the day, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators are neutral. Fundamentally, revenue and net income have declined from 2022 peaks, though Q2 2026 earnings beat expectations. Recent news includes a cybersecurity incident and expansion efforts in Brazil, adding to volatility. Valuation ratios like P/E of 11.11 and P/S of 0.97 suggest potential undervaluation relative to historical metrics.
The outlook for EC is cautious; analyst consensus is mixed with a $15 price target below the current price. Risks include declining revenue trends, high debt levels, and operational disruptions from recent cyber threats. Opportunities lie in cost management and strategic acquisitions, but investor sentiment remains divided. The stock's near-term performance hinges on execution stability and energy market conditions.
Zimmer Biomet (ZBH) trades at $96.55, down 0.66% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.07, and raised its full-year outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology, though net income margin has moderated from 2023 peaks. Recent corporate news includes a dividend declaration and expansion of its technology center in India.
The outlook for ZBH is positive, driven by consistent earnings beats and strategic growth initiatives, but investors face risks from margin pressure and increasing debt levels. The stock offers potential upside to the consensus target, supported by institutional accumulation, though competitive and macroeconomic headwinds in the medtech sector warrant caution.
Trailing returns across standard periods
Latest headlines on both assets
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →